That question eventually became ResilienceXAI, an open-source AI simulation platform designed to help organizations ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shira is eager to hear from college students and their families about how you’re feeling about the job market. Drop her a line at shira.ovide@washpost.com. A lot of students took the advice to learn ...

Expand your knowledge of the full lifecycle of software development – from design and testing to deployment and maintenance – with a hands-on, 30-credit online Master of Science (MS) in Computer ...

Something strange happened at University of California campuses this fall. For the first time since the dot-com crash, computer science enrollment dropped. System-wide, it fell 6% last year after ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Transaction value is based on the SEC Form 4 weighted average purchase price ($6.04) as reported for the transaction on October 10, 2025. How does the scale of this transaction compare to Christopher ...